利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

96 条记录 (耗时 0.033 秒)

    NEISSERIAL VACCINES
    7.
    发明公开
    NEISSERIAL VACCINES 审中-公开
    奈瑟-IMPFSTOFF

    公开(公告)号：EP2481419A3

    公开(公告)日：2013-04-10

    申请号：EP12157807.4

    申请日：2003-07-31

    申请人： GlaxoSmithKline Biologicals S.A.

    发明人： Biemans, Ralph ,  Denoel, Philippe ,  Feron, Christiane ,  Goraj, Carine ,  Poolman, Jan ,  Weynants, Vincent

    IPC分类号： A61K39/095 ,  A61P31/04

    CPC分类号： A61K39/095 ,  A61K39/102 ,  A61K39/1045 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/22 ,  Y02A50/396

    摘要： The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA & OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. The FrpB downregulation is also described. Alternatively, or in addition, IgtB - is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from IgtB - and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

    摘要翻译： 本发明涉及用于治疗和预防奈瑟氏球菌病的免疫原性组合物和疫苗。 本发明的免疫原性组合物含有选自至少两种不同类型的抗原的抗原的组合，包括粘附素，自体转运蛋白，毒素，铁获得蛋白和膜相关蛋白（优选整体外膜蛋白）。 抗原的这种组合能够针对奈桑氏生命周期的不同方面靶向免疫应答，导致更有效的免疫应答。